{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:03Z","timestamp":1787028723178,"version":"build-2736575974"},"reference-count":23,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Background: Invasive fungal infections (IFI) following allogeneic stem cell transplant (allo-HCT) are associated with high morbidity and mortality. Primary prophylaxis using voriconazole has been shown to decrease the incidence of IFI. Methods: We conducted a retrospective analysis at the Bone Marrow Transplant (BMT) unit of the American University of Beirut including 195 patients who underwent allo-HCT for hematological malignancies and received voriconazole as primary prophylaxis for IFI. The primary endpoints were based on the incidence of IFI at day 100 and day 180, and the secondary endpoint based on fungal-free survival. Results: For the study, 195 patients who underwent allo-HCT between January 2015 and March 2021 were included. The median age at transplant was 43 years. Of the patients, 63% were male, and the majority of patients were diagnosed with acute myeloid leukemia (AML) (60%). Voriconazole was given for a median of 90 days and was interrupted in 20 patients. The majority of IFI cases were probable invasive aspergillosis (8%). The incidence of IFI including proven, probable and possible IFI was 34%. The incidence of proven and probable IFI was 5% were 8%, respectively. The incidence of proven-probable (PP-IFI) was 5.1% at day 100 and 6.6% at day 180. The majority of PP-IFI cases were invasive aspergillosis (8%). A univariate analysis of patients, transplant characteristics and IFI showed a significant correlation between the type of donor, disease status before transplant, graft-versus-host disease prophylaxis used and incidence of IFI. Only disease status post-transplant showed a significant correlation with fungal-free survival in the multivariate analysis. Conclusion: Primary prophylaxis with voriconazole in allo-HCT is associated with a low incidence of IFI. More studies are required to compare various antifungal agents in this setting.<\/jats:p>","DOI":"10.3390\/jof7110925","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:21:34Z","timestamp":1635805294000},"page":"925","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center\u2019s Experience"],"prefix":"10.3390","volume":"7","author":[{"given":"Ali","family":"Atoui","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Omeirat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Fakhreddine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4296-6095","authenticated-orcid":false,"given":"Raquelle","family":"El Alam","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Kanafani","sequence":"additional","affiliation":[{"name":"Infectious Disease, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Abou Dalle","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[{"name":"Infectious Disease, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo Italiano trapianto midollo osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation","volume":"44","author":"Fleming","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_3","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2014.02.018","article-title":"Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: Revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/1806-9282.62.07.641","article-title":"Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center","volume":"62","author":"Branca","year":"2016","journal-title":"Rev. Assoc. M\u00e9dica Bras."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study--sorveglianza epidemiologica infezioni fungine nelle emopatie maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Axell-House, D., Wurster, S., Jiang, Y., Kyvernitakis, A., Lewis, R., Tarrand, J., Raad, I., and Kontoyiannis, D. (2021). Breakthrough mucormycosis developing on mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer. J. Fungi, 7.","DOI":"10.3390\/jof7030217"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s15010-018-1195-4","article-title":"Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: A case series","volume":"46","author":"Ibrahim","year":"2018","journal-title":"Infection"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.jiph.2019.05.007","article-title":"Epidemiology and burden of invasive fungal infections in the countries of the Arab League","volume":"13","author":"Kmeid","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2007.06812.x","article-title":"Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients","volume":"139","author":"Barnes","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbmt.2004.02.006","article-title":"Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center","volume":"10","author":"Fukuda","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/bmt.2013.51","article-title":"Hematopoietic SCT in Europe: Data and trends in 2011","volume":"48","author":"Passweg","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/tid.12003","article-title":"Infectious complications following allogeneic stem cell transplantation: Reduced-intensity vs. myeloablative conditioning regimens","volume":"15","author":"Kim","year":"2013","journal-title":"Transpl. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/14787210.2017.1305886","article-title":"Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Marks","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bow, E.J., Vanness, D.J., Slavin, M., Cordonnier, C., Cornely, O.A., I Marks, D., Pagliuca, A., Solano, C., Cragin, L., and Shaul, A.J. (2015). Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0855-6"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2017652","DOI":"10.1001\/jamanetworkopen.2020.17652","article-title":"Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: A systematic review and network meta-analysis","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/mmy\/myaa008","article-title":"Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm","volume":"58","author":"Chan","year":"2020","journal-title":"Med Mycol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1093\/ofid\/ofz360.1596","article-title":"1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?","volume":"6","author":"Hadjivassiliou","year":"2019","journal-title":"Open Forum Infect. Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/11\/925\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:24:03Z","timestamp":1760167443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/11\/925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jof7110925"],"URL":"https:\/\/doi.org\/10.3390\/jof7110925","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]}}}